When most people think about nuclear power, they imagine massive cooling towers rising above the horizon.

They picture billion-dollar construction projects, decades-long permitting battles, and reactors capable of powering entire metropolitan areas.

Even today’s much-discussed small modular reactors (SMRs) somewhat fit that basic mold…

Yes. They’re smaller than conventional reactors, but they’re still utility-scale assets designed to serve regional grids.

Micro modular reactors, however, are different…

In fact, they may represent one of the most overlooked investment opportunities in the entire energy sector.

While investors focus on the race to build the next generation of SMRs, a smaller and potentially more disruptive technology is quietly advancing through testing, licensing, and early deployment.

You see, these reactors aren’t being designed to power cities. They’re being designed to power everything else…

Remote mines. Military bases. Data centers. Ports. Arctic communities. Oil and gas operations. Desalination facilities. Critical infrastructure.

And perhaps someday, even the Moon.

Because the companies pursuing this technology believe the future of nuclear energy isn’t just bigger…

It’s smaller. Much smaller.

And that distinction could create an entirely new market worth hundreds of billions of dollars over the coming decades.

A Different Kind of Nuclear Revolution

Most advanced reactor companies are chasing a familiar goal: they want to build power plants.

But microreactor developers are chasing something entirely different…

They want to replace diesel generators.

That may sound less exciting, but it could ultimately prove more profitable.

You see, today, thousands of remote operations around the world rely on diesel fuel because they have no practical alternative. 

Mines in northern Canada. Military installations in remote regions. Islands disconnected from major grids. Arctic settlements. Energy projects far from transmission infrastructure.

The fuel must be shipped, trucked, flown, stored, protected, and eventually burned.

Every step adds cost. Every step adds risk. And every step creates an opportunity for disruption.

But micro modular reactors offer a radically different approach…

Many designs are intended to operate for years before requiring refueling. 

Some can be transported in shipping containers, while others are designed to be factory-built and deployed almost like industrial equipment rather than traditional power plants.

The Department of Energy has repeatedly identified remote communities, defense installations, and industrial facilities as among the most promising early markets for microreactors. 

Meanwhile, developers are increasingly targeting another customer that barely existed a decade ago: Artificial intelligence.

As AI infrastructure expands, data centers are becoming some of the largest electricity consumers on Earth. But the challenge isn’t simply finding power.

It’s finding reliable power. Twenty-four hours a day. Seven days a week.

Regardless of weather. Regardless of grid congestion. Regardless of geography.

And that is exactly the kind of problem nuclear power was built to solve.

The Hidden Connection to the Commodity Supercycle

Regular readers know we’ve spent years discussing what we believe is a developing commodity supercycle.

The world is demanding more copper. More uranium. More silver. More aluminum. More nickel. More rare earths. More energy.

But what often gets overlooked is where those materials come from…

The next generation of critical mineral deposits won’t necessarily be located beside major population centers or existing power infrastructure.

Many will be developed in remote regions where electricity is scarce, unreliable, or prohibitively expensive.

And that creates an interesting feedback loop…

The commodity boom requires more mines. Those mines require more power. Microreactors could provide that power.

Which in turn enables the production of more commodities needed to build AI infrastructure, electrical systems, advanced manufacturing facilities, and additional nuclear reactors.

The result is a self-reinforcing cycle that shows the commodity story and the nuclear story may be far more connected than most investors realize.

The Military Opportunity

Historically, military spending has often accelerated technological development.

The internet. GPS. Jet engines. Semiconductors. Nuclear energy itself.

Well, microreactors may eventually join that list…

The U.S. Department of Defense has emerged as one of the most important early customers for advanced nuclear technologies.

Project Pele, one of the Pentagon’s flagship microreactor initiatives, is designed to demonstrate transportable nuclear power for military operations. 

BWX Technologies is currently manufacturing the reactor core for the project, with power generation expected later this decade.

The appeal is obvious…

Modern military operations consume enormous amounts of energy. Fuel convoys remain vulnerable. Remote bases often depend on diesel generators.

Communications networks, sensors, and advanced weapons systems require increasingly reliable power sources.

And a compact reactor that can operate for years with minimal fuel requirements offers strategic advantages that traditional generators simply can’t match.

For investors, military adoption matters for another reason, too…

Government customers often help technologies survive long enough to reach commercial scale.

The Public Companies Investors Can Watch

The most direct publicly traded microreactor exposure today is probably BWX Technologies…

Unlike many advanced reactor developers, BWXT already operates a substantial business supplying nuclear technology to the U.S. government and naval nuclear programs. 

Its involvement in Project Pele gives investors exposure to one of the most visible microreactor demonstrations currently underway.

Another important name is Oklo…

While Oklo is often grouped with the broader advanced reactor industry, its Aurora system targets many of the same end markets that make microreactors attractive: industrial facilities, data centers, remote sites, and military applications. Investors increasingly view the company as a potential bridge between the AI boom and advanced nuclear power.

Then there is NANO Nuclear Energy…

NANO has become one of the purest public microreactor stories available to retail investors. 

The company describes itself as the first publicly listed U.S. microreactor developer and is pursuing multiple reactor concepts, including the KRONOS MMR platform. 

Its recent regulatory progress at the University of Illinois represents one of the more tangible milestones in the sector.

Investors should understand that NANO remains highly speculative. Like many early-stage reactor developers, it is years away from large-scale commercialization.

But that doesn’t necessarily make it a bad investment. It simply makes it a venture-style investment masquerading as a public stock.

That’s a very different risk profile from a company like BWXT.

Finally, investors should not overlook the picks-and-shovels side of the industry…

Companies such as Centrus Energy and Cameco Corp. will ultimately benefit regardless of which reactor developer wins.

Because nearly all advanced reactor pathways require specialized fuel, enrichment capacity, transportation infrastructure, and fuel-cycle services.

The Private Company That Caught My Attention

Among the private companies pursuing microreactor technology, one stands out because of its unusually asymmetric setup…

That company is Nuclea Energy. And we’ve discussed Nuclea before, but its story deserves another look.

Because it is developing what it calls the Morpheus reactor, a microreactor specifically designed for some of the most compelling early-use cases in the industry…

Remote communities, mining operations, AI data centers, and military installations.

But what makes Nuclea interesting isn’t simply the technology…

It’s the market selection.

Many advanced reactor companies are competing for utility contracts that may take years or even decades to materialize.

Nuclea appears focused on customers who already have an expensive power problem today.

Mining companies don’t need convincing that electricity matters.

Data center operators don’t need convincing that reliability matters.

Military planners don’t need convincing that energy security matters.

The demand already exists. The challenge is delivering a solution.

That’s why I view Nuclea as an asymmetric opportunity…

If microreactors fail to gain widespread adoption, companies like Nuclea may never become major businesses.

But if even a fraction of the targeted markets adopt nuclear microreactors, the addressable opportunity becomes enormous.

The risk is obvious. But the potential reward is difficult to quantify.

And those are often the characteristics that define the most interesting early-stage opportunities.

Why Investors Should Pay Attention Now

Microreactors remain years away from widespread deployment.

Many designs will fail. Some companies will disappear.

Licensing challenges remain significant. Fuel supply remains a bottleneck.

Economics still need to be proven at scale.

Those are real risks.

But that is precisely why the opportunity exists.

Investors tend to notice trends only after they become obvious.

Today, most discussions about nuclear power revolve around large reactors, SMRs, and AI-driven electricity demand.

Microreactors rarely make headlines.

Yet they may ultimately become the technology that extends nuclear power into places it has never reached before.

Not because they replace traditional reactors. Because they serve markets traditional reactors never could.

That distinction may prove far more important than investors currently appreciate.

And if the next decade unfolds the way many energy experts expect, micro modular reactors may become one of the most fascinating—and potentially profitable—corners of the entire nuclear renaissance.

For years, investors have debated the future of cryptocurrency and the companies that “mine” it…

The bullish camp argued that Bitcoin would continue climbing and reward those willing to invest billions of dollars in specialized computing equipment. 

But the bears countered that mining would eventually become a commodity business, squeezed by rising competition, increasing energy costs, and the inevitable consolidation that follows every technology boom.

As is often the case, both sides were right…

The Infrastructure Everyone Overlooked

Bitcoin has matured into a widely accepted asset class, institutional investors have embraced it, and exchange-traded funds have opened the door to billions of dollars of new capital. 

At the same time, the explosive era of thousands of competing cryptocurrencies has largely come to an end. 

And many of the altcoins that once promised to reshape finance have disappeared entirely, while others survive only as shadows of their former selves.

For many mining companies, that changing landscape presents a challenge.

For investors, however, it may present an opportunity.

Because while the value of many cryptocurrencies has faded, the physical infrastructure built to support them has become more valuable than ever.

A Server Rack Is Just a Server Rack

At first glance, cryptocurrency mining and artificial intelligence appear to be completely different businesses…

One validates blockchain transactions and solves cryptographic problems. The other trains language models, powers recommendation engines, and performs complex data analysis.

But if you walk into one of their facilities, the similarities become glaringly obvious…

Both businesses depend on rows of densely packed servers operating around the clock. 

Both require enormous amounts of electricity delivered reliably and at industrial scale. 

Both generate tremendous amounts of heat that must be removed efficiently. 

Both require high-speed networking, physical security, backup systems, and the ability to operate continuously with minimal downtime.

The workloads may be different, but the infrastructure is remarkably similar.

And in many cases, the buildings themselves require surprisingly few modifications to transition from one business to the other…

Specialized ASIC mining equipment can be removed and replaced with GPU clusters or other high-performance computing hardware while the underlying electrical systems, cooling infrastructure, networking, and real estate remain largely unchanged.

That’s a pretty huge advantage when today’s AI economy is facing a shortage that has very little to do with chips…

And very much to do with needing places to put them.

The Real Constraint Is Power

Nearly every announcement from the world’s largest technology companies points toward the same conclusion…

Artificial intelligence will require vastly more computing capacity than exists today.

Microsoft, Amazon, Meta, Oracle, OpenAI, xAI, and dozens of emerging AI developers are collectively planning data center expansions measured not in square feet but in gigawatts of electricity.

And while finding processors and places to put them is difficult, finding enough power to operate them may be even harder…

Utilities across North America are reporting years-long wait times for new industrial connections. 

Developers routinely discover that obtaining the necessary permits, transmission upgrades, and interconnection agreements can take longer than constructing the buildings themselves.

And that changes the value proposition of existing cryptocurrency facilities…

Many mining companies spent years searching for locations with inexpensive, abundant electricity because power represented their single largest operating expense. 

They negotiated utility agreements, secured transmission capacity, built substations, and established industrial campuses capable of supporting continuous high-density computing.

And those assets are becoming increasingly attractive to AI developers looking for a faster path to deployment.

Geography Could Separate the Winners

Not every cryptocurrency miner is equally positioned to benefit from this trend, though…

The companies with the greatest opportunity are likely to be those that built their operations in locations naturally suited for large-scale computing.

Northern climates reduce cooling costs…

Hydroelectric regions provide inexpensive and reliable power…

Areas with abundant water resources offer additional cooling flexibility…

Remote industrial sites often provide inexpensive land and room for expansion…

These were attractive characteristics for cryptocurrency miners long before artificial intelligence became a global investment theme.

Now they may become significant competitive advantages.

Because, rather than spending years assembling land, negotiating power contracts, and constructing new facilities from the ground up…

AI developers can potentially partner with or lease capacity from companies that already possess much of the necessary infrastructure.

Companies Already Beginning the Transition

But we’re not the only ones with this thought…

In fact, several publicly traded companies have recognized this opportunity and are actively repositioning themselves as providers of digital infrastructure rather than simply cryptocurrency miners…

Bitzero (OTC: BTZRF) has built its operations around renewable hydroelectric power and locations that offer abundant energy and favorable cooling characteristics. 

The company’s original strategy emphasized environmentally responsible Bitcoin mining, but those same facilities are well suited for high-performance computing applications.

As demand for AI infrastructure continues to accelerate, Bitzero has an opportunity to evolve into a diversified compute platform that serves both cryptocurrency and artificial intelligence markets. 

Rather than abandoning Bitcoin mining, the company could leverage existing campuses to generate multiple revenue streams while maximizing utilization of its power assets.

For investors, that creates exposure not only to digital assets but also to one of the fastest-growing infrastructure markets in the world.

Bitzero is still mostly flying under the radar, but another company, Core Scientific (NASDAQ: CORZ) has become perhaps the most visible example of this transformation… 

After restructuring its business, the company began pursuing long-term high-performance computing agreements alongside its traditional mining operations.

The market has increasingly rewarded that strategy because recurring AI infrastructure revenue tends to be viewed as more predictable and potentially more valuable than revenue tied solely to cryptocurrency prices.

Not to be outdone, Hive Digital Technologies (NASDAQ: HIVE) recognized early that graphics processing units could generate revenue outside of cryptocurrency mining. 

The company has steadily expanded its GPU cloud computing business, renting computing capacity to artificial intelligence and enterprise customers while maintaining exposure to digital assets.

Its evolution illustrates how existing infrastructure can be repurposed rather than replaced.

Hut 8 (NASDAQ: HUT) has also gradually repositioned itself as a broader digital infrastructure company with assets that extend beyond Bitcoin production. 

Data centers, power agreements, and high-performance computing services are becoming increasingly important components of its long-term strategy.

Iris Energy (NASDAQ: IREN) is another. It’s a sustainable data center company that used to be focused on crypto mining.

They company developed renewable-powered campuses specifically designed around abundant electricity and scalable infrastructure to power mining operations. 

Those characteristics now position the company to participate in growing demand for AI computing capacity while continuing to operate cryptocurrency mining businesses.

A Familiar Pattern for Investors

History offers countless examples of one industry’s excess capacity becoming the foundation for the next technological revolution…

Railroads built for westward expansion ultimately enabled national commerce.

Fiber-optic networks installed during the dot-com bubble became the backbone of cloud computing and streaming media.

Natural gas pipelines constructed for one generation of energy demand later supplied entirely different industries.

And today, cryptocurrency mining infrastructure seems likely to follow a similar path…

What was originally built to secure decentralized financial networks could become the physical foundation supporting artificial intelligence, cloud services, scientific computing, and enterprise data processing.

The market often focuses on the newest technology while overlooking the infrastructure that makes it possible.

Yet history shows that infrastructure owners frequently become some of the largest long-term beneficiaries of technological change.

Why Investors Should Pay Attention

The cryptocurrency sector is no longer defined by speculative excitement alone. 

It’s increasingly becoming part of a broader digital infrastructure ecosystem that includes cloud computing, artificial intelligence, and high-performance data processing.

And companies that successfully execute this transition could potentially benefit from two powerful secular trends at the same time…

Continued adoption of digital assets and the extraordinary growth in AI computing demand.

Not every miner will make that transition successfully, and significant capital investment will still be required to convert specialized facilities into world-class AI data centers.

But the companies that already possess abundant power, scalable campuses, efficient cooling systems, and experienced infrastructure teams begin the race with a massive head start.

The crypto boom may have built far more than a new financial system…

It may have quietly built the next generation of AI infrastructure, years before most investors even realized they’d need it.

Article:

Every few years, Wall Street falls in love with a new biotechnology buzzword.

First it was gene therapy. Then CAR-T cells. 

And more recently, it’s been natural killer cells, or NK cells, the immune system’s first responders that patrol the body looking for infected or cancerous cells to destroy.

Investors have poured billions of dollars into companies developing NK cell therapies, convinced they could become the next major breakthrough in oncology.

But there’s a problem…

Most of these treatments are incredibly complicated.

Doctors must collect living immune cells from donors or patients, expand or genetically engineer them inside specialized laboratories, freeze them, ship them across the country, thaw them, and finally infuse them back into the patient. 

It’s as much a manufacturing business as it is a pharmaceutical business.

And that complexity drives up costs, limits availability, and creates logistical nightmares that have prevented many promising cell therapies from reaching large numbers of patients.

But one tiny biotech is taking a completely different approach…

Rather than building a better NK cell factory, GT Biopharma (NASDAQ: GTBP) is trying to eliminate the factory altogether.

Recruiting the Army That’s Already There

Instead of manufacturing billions of natural killer cells outside the body…

GT Biopharma’s proprietary TriKE platform is designed to recruit and activate the NK cells that already exist inside every patient.

Think of it as the difference between building an entirely new army and simply giving better weapons and clearer instructions to the soldiers already on the battlefield…

You see, each TriKE molecule contains three distinct components working together.

One end attaches to CD16 receptors found on natural killer cells. 

The opposite end attaches to proteins expressed on cancer cells. 

Between them sits wild-type IL-15, an immune signaling protein that stimulates NK cell proliferation, survival, and persistence. 

So, rather than simply telling immune cells where to attack, the molecule also encourages them to multiply and remain active longer.

And that distinction may sound subtle, but it represents an entirely different philosophy of cancer treatment…

GT Biopharma isn’t developing a cell therapy.

It’s developing what could become an off-the-shelf immune engager.

A Simpler Path to Scale

If successful, this approach could solve one of the biggest challenges facing cellular immunotherapy…

Traditional NK cell companies must manufacture living products that require specialized facilities, cold-chain transportation, and careful handling from production to infusion.

But GT Biopharma’s TriKE molecules are recombinant proteins.

That means doctors could theoretically administer them much like other biologic drugs without waiting weeks for customized cell manufacturing.

For investors, that means the company isn’t simply competing with other NK cell developers… 

It’s attempting to create a pharmaceutical product that could be easier to manufacture, distribute, and scale worldwide.

And that’s a very different investment thesis…

The Secret Hidden in a Llama

One of the more fascinating aspects of the platform has nothing to do with cancer at all.

It has to do with camels…

More specifically, camelids such as llamas and alpacas naturally produce unusually small antibodies known as nanobodies.

Because they’re significantly smaller than traditional antibodies, these nanobodies can remain stable while reaching biological targets that larger molecules sometimes struggle to access.

GT Biopharma built its second-generation TriKE platform around these camelid nanobodies, creating compact molecules designed to engage natural killer cells while simultaneously targeting cancer cells and delivering IL-15 stimulation.

It’s an unusual technological foundation that differentiates the company from many other small immunotherapy developers.

From Blood Cancers to Solid Tumors

The company’s first clinical efforts focused on blood cancers like acute myeloid leukemia and high-risk myelodysplastic syndrome using GTB-3650.

But now that the groundwork has been laid, management is pursuing a much larger opportunity…

Its newest candidate, GTB-5550, targets B7-H3, a protein expressed across numerous difficult-to-treat solid tumors including prostate, ovarian, pancreatic, breast, bladder, head and neck, and non-small cell lung cancers.

The first patient entered the Phase 1 basket study in May 2026, making GTB-5550 the first dual nanobody TriKE tested using subcutaneous dosing rather than intravenous administration.

And that may not grab headlines today, but it dramatically expands the company’s addressable market…

Instead of pursuing one rare blood cancer indication, GT Biopharma is building a platform that could be adapted across numerous solid tumor types.

A Platform Rather Than a Product

And that’s perhaps the most overlooked aspect of GT Biopharma…

Investors aren’t simply buying a single experimental drug. They’re buying a modular technology platform.

The TriKE architecture allows researchers to swap different tumor-targeting components while preserving the same natural killer cell activation mechanism. 

The company already has multiple clinical and preclinical programs targeting blood cancers and solid tumors, illustrating how the platform can be adapted to a wide range of malignancies.

For a micro-cap biotechnology company, that provides multiple shots on goal rather than relying entirely on one make-or-break clinical program.

Why Investors Should Pay Attention

Small biotechnology companies are always speculative investments, and GT Biopharma remains an early-stage clinical company with all the risks that implies…

Clinical failures, financing needs, and regulatory setbacks are common throughout the industry.

But investors looking at GT Biopharma should resist the temptation to classify it as simply another NK cell developer…

The more interesting story is that the company is attempting to remove one of immunotherapy’s biggest bottlenecks.

If today’s generation of NK therapies depends on building immune cells in factories, GT Biopharma is betting tomorrow’s therapies may simply recruit the army already living inside the patient.

That’s an ambitious vision.

And if it works, this little-known biotech could end up changing not just who wins the NK cell race, but how the whole race is run.

Everyone has heard about Small Modular Reactors, or SMRs, because they’re one of the hottest stories in the energy market…

Governments are backing them. Technology companies are talking about them. Utilities are studying them. Investors have poured billions into companies developing them.

And for good reason: The world suddenly needs far more electricity than anyone expected.

Artificial intelligence data centers are consuming enormous amounts of power. 

Manufacturing is returning to North America. 

Countries are electrifying transportation systems. 

At the same time, governments want reliable, carbon-free electricity that doesn’t depend on the weather.

And nuclear power checks all those boxes…

Unlike wind and solar, nuclear plants run 24 hours a day. 

Unlike natural gas, they don’t require constant fuel deliveries. 

Unlike coal, they produce virtually no emissions during operation.

The problem is that traditional nuclear plants are massive, expensive, and can take a decade or longer to build.

And that’s where SMRs entered the conversation…

Small Modular Reactors are designed to be manufactured in factories, shipped to project sites, and assembled much more quickly than conventional nuclear plants. 

Many can generate enough electricity to power hundreds of thousands of homes while occupying a fraction of the footprint of traditional reactors.

And the excitement surrounding SMRs is justified.

But many investors are already looking there.

The less crowded opportunity may be one step smaller… And potentially much bigger.

Meet The Little Brother of The SMR

If SMRs are the work vans of the nuclear world, Micro Modular Reactors, or MMRs, are the all-terrain vehicles.

They’re smaller, more mobile, and capable of going places traditional power systems simply can’t.

While most SMRs are designed to generate between roughly 50 and 300 megawatts of electricity, MMRs are often measured in single digits or tens of megawatts.

And that may sound like a disadvantage… but it’s actually their superpower.

Because they’re smaller, MMRs can be deployed where larger reactors, and even SMRs, would never make economic sense.

They can power remote mining operations.

They can supply electricity to military installations.

They can support isolated communities.

They can serve industrial facilities located far from major power grids.

Some designs are even intended to be fully transportable, allowing them to be moved to where power is needed most without disassembly and reassembly delaying timelines.

Think of them less as miniature power plants and more as portable energy infrastructure…

Like a giant battery that only needs to be recharged every five years or so.

Because that’s where the real opportunity begins.

The AI Boom Needs More Than Gigawatt Reactors

When investors think about nuclear power and artificial intelligence, they usually imagine massive reactors supplying power to giant data center campuses.

And that will certainly happen.

But AI’s energy needs extend far beyond hyperscale facilities…

Smaller data centers are appearing in places where grid infrastructure is weak. 

Edge computing facilities are being built closer to users to reduce latency. 

Military AI systems are moving into the field.

All these applications need reliable electricity.

Many of them can’t wait years for utilities to build new transmission lines.

But an MMR could provide dedicated power directly at the site.

So, instead of spending billions on transmission upgrades, operators could potentially bring the power source to the computing infrastructure.

And that changes the economics dramatically…

As AI expands into every corner of the economy, the demand for distributed power could become just as important as demand for centralized generation.

The Mining Industry May Become the First Major Customer

To be perfectly honest, one of the most exciting applications for MMRs has nothing to do with technology…

It’s mining.

Many of the world’s most valuable mineral deposits are located in remote regions with little or no access to reliable power.

Because of this, mining companies often rely on diesel generators operating around the clock.

The fuel must be transported long distances by truck, rail, or ship. Costs can be enormous. Logistics can be complicated. And environmental concerns are constant.

Now imagine replacing those diesel generators with a compact reactor capable of operating for years between refueling cycles.

The economics become compelling very quickly.

And this is especially important because the world desperately needs more copper, uranium, silver, rare earth elements, lithium, and other critical minerals.

Many of those future mines will be in regions where energy infrastructure is limited at best.

And MMRs could become the missing piece that unlocks development of resources previously considered uneconomic.

In other words, microreactors may not just benefit from the critical minerals boom…

They could help create it.

Why Militaries Are Paying Attention

Defense planners around the world have another problem…

Modern military operations consume enormous amounts of energy.

Forward operating bases require electricity for communications, radar systems, air defenses, drones, water purification, and increasingly sophisticated computing equipment.

Historically, that energy has come from fuel convoys.

But fuel convoys create vulnerabilities…

Every truck delivering diesel becomes a potential target.

Microreactors offer a different solution…

A reactor capable of operating safely for years could dramatically reduce logistical requirements while providing reliable power in severe environments.

That’s one reason defense agencies around the world have shown increasing interest in advanced nuclear technologies…

Energy independence is becoming a national security priority.

And few technologies offer greater energy independence than a compact reactor operating far from traditional supply chains.

The Race to Remote Communities

There are thousands of remote communities across North America and around the world that depend on diesel generation.

Many pay electricity costs several times higher than those enjoyed by residents of major cities.

Fuel deliveries can be interrupted by weather. Costs fluctuate with oil prices. And infrastructure is expensive to maintain.

But MMRs could provide a cleaner, more reliable alternative…

Instead of importing fuel every few weeks, communities could potentially operate for years with minimal intervention.

For regions located above the Arctic Circle, on islands, or in other isolated locations, that possibility is enormously attractive.

And that means the market may be much larger than even the smartest investors realize.

The Opportunity Is Still Early

The beauty of the MMR story is that it’s still in its infancy…

Unlike many SMR companies that have already attracted substantial attention, the microreactor ecosystem remains relatively unknown.

A handful of established nuclear companies are developing designs.

Several venture-backed startups are advancing innovative concepts.

Some private firms are positioning themselves for public listings.

Others could become acquisition targets for larger nuclear and industrial companies seeking to expand their capabilities.

We’ve all seen this movie before, just with slightly different characters…

During the early days of the shale revolution, most investors focused on major oil companies while smaller innovators quietly built fortunes.

The same thing happened in solar power, artificial intelligence, cybersecurity, and countless other transformative technologies.

The biggest gains often come before the crowd realizes a new market exists.

Now, that doesn’t mean every microreactor company will succeed. Many will likely fail…

But it does mean investors willing to study the space today have an opportunity to identify tomorrow’s leaders before Wall Street fully appreciates the size of the market.

A Nuclear Future That’s Bigger Than Most People Realize

For years, the nuclear investment conversation focused almost entirely on large reactors. Then attention shifted toward SMRs. Now another chapter is beginning…

Micro Modular Reactors represent a fundamentally different vision of energy production. 

Instead of building enormous power plants and transmitting electricity over vast distances, they bring reliable power directly to where it’s needed.

Whether it’s an AI data center, a critical minerals mine, a military installation, an industrial facility, or a remote community, the potential applications continue to expand.

The world needs more energy. Much more energy.

And while SMRs may grab most of the headlines today, investors should remember that some of the biggest opportunities emerge from technologies that are still flying under the radar.

Microreactors may be one of them. And the companies developing these systems today could become some of the most important energy providers of tomorrow.

The biggest news in the markets today is SpaceX’s much‑anticipated IPO filing.

The company is aiming to raise roughly $75 billion at about a $1.75 trillion valuation, which would make it the largest IPO in history.

In its S‑1, filed May 20, 2026, SpaceX reports 2025 revenue in the high‑teens billions and a net loss of around $4.9 billion dollars, with a cumulative deficit in the tens of billions.

Interestingly, it seems that Rocket Man Elon’s biggest revenue generator wasn’t rockets at all … rather, the filing shows that connectivity (i.e. Starlink satellite internet) generated about $11.4 billion of revenue in 2025 and several billion dollars of operating income, while the launch and AI segments together still lost money.

In other words, the only clearly profitable pillar of Elon Musk’s space empire right now is a satellite internet business.

Starlink is printing cash for Musk, and that cash is helping fund rockets, deep‑space projects, and an aggressive AI build‑out.

Don’t think that Jeff Bezos missed the memo. Amazon is pouring billions into its 3,200‑plus‑satellite Project Kuiper constellation, turning low‑Earth‑orbit broadband into a full‑blown corporate space race.

So while most eyes this morning are glued to that $1.75 trillion figure with visions of massive rockets flying through the air …

… The real story might just be the impact that small low earth orbit (LEO) satellites are poised to make on a “space economy” that McKinsey estimates at $1.8 trillion.

And the good news is you don’t have to wait until SpaceX finally goes public to gain exposure to this market.

Just down the road from SpaceX and NASA at Cape Canaveral, there is a much smaller company positioning itself for the same satellite economy that Starlink just validated to the tune of multiple billions of dollars.

Starfighters Space (NASDAQ: FJET) is headquartered at Kennedy Space Center in Florida, operating out of a reusable launch vehicle hangar on Hangar Road in Cape Canaveral.

The company runs what it describes as the world’s only commercial fleet of flight‑ready F‑104 Starfighter supersonic aircraft, capable of sustained Mach 2 flight.

Starfighters Space (NASDAQ: FJET)  currently operates seven modified F‑104s that can be configured as first‑stage lifting platforms.

These jets are designed to carry small rockets and payloads to about 45,000 feet for air‑launch to space.

The goal is to enable sub‑orbital launches to around 100 kilometers with a system called STARLAUNCH 1, and then to reach low Earth orbit (160 kilometers and above) with a next‑generation system called STARLAUNCH 2, which is expected to offer roughly 49 percent more thrust.

In late 2025 and early 2026, the company announced milestones for its STARLAUNCH I program, including completion of preliminary designs, manufacture of test articles with GE Aerospace’s Innoveering unit, and plans for wind‑tunnel work and drop tests.

Starfighters Space (NASDAQ: FJET)  is also already generating revenue from adjacent activities. It offers pilot and astronaut training, in‑flight testing, and other aeronautics services to defense, civil, academic, and commercial customers.

Its F‑104 fleet supports hypersonic and high‑altitude test programs, and the company says that it is “market‑ready with minimal R&D effort” for its core flight operations while STARLAUNCH matures.

And this little-known company sits directly in the path of the trend SpaceX filing is igniting.

As more low‑Earth‑orbit constellations are funded—whether it is Starlink, Amazon’s 3,200‑plus‑satellite Amazon Leo project, or other regional and specialized networks — every one of those satellites needs a ride to orbit.

Large rockets will handle a lot of bulk deployment, but there is also demand for more targeted launches: smaller payloads, specific orbits, and more flexible timing.

This is the niche Starfighters Space (NASDAQ: FJET)  is aiming at.

And, with the SpaceX IPO filed, the fuse is officially lit for this niche to explode.

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of Starfighters Space, Inc. (NYSE: FJET). This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Starfighters Space, Inc. (NYSE: FJET) is the sole source of funds for a budget of approximately $725,000 provided to CDMG INC the advertising agency to cover the costs associated with creating, printing and distribution of this advertisement. The advertising agency will retain any excess sums after all expenses are paid. Readers should beware that the advertising agency and/or its owners ,officers, principals, or affiliates own shares and/or stock options of Starfighters Space, Inc. (NYSE: FJET) and therefore have an additional incentive to see the company’s stock perform well. This share ownership should be viewed as a major conflict with our ability to be unbiased. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. While this advertisement is being disseminated and for a period of not less than 90 days thereafter, the advertising agency and their respective officers, principals, or affiliates will not sell securities of Starfighters Space, Inc. (NYSE: FJET). If successful, this advertisement will increase investor and market awareness of Starfighters Space, Inc. (NYSE: FJET) and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement and the advertising agency do not purport to provide a complete analysis of Starfighters Space, Inc. (NYSE: FJET) or its financial position. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about Starfighters Space, Inc. (NYSE: FJET). Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in Starfighters Space, Inc. (NYSE: FJET) SEC filings. Investing in microcap securities such as Starfighters Space, Inc. (NYSE: FJET) is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agency cannot guarantee the accuracy or completeness of the information and is not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of Starfighters Space, Inc. (NYSE: FJET) and/or its industry. The advertising agency notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect Starfighters Space, Inc. (NYSE: FJET) actual results of operations. Factors that could cause actual results to vary include the size and growth of the market Starfighters Space, Inc. (NYSE: FJET) products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agency is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.

For years, investors chased the giant pharmaceutical companies…

They bought the household names with massive balance sheets, billion-dollar drug portfolios, and global sales teams. 

But lately, some of the biggest gains in healthcare haven’t come from the giants themselves…

Instead, they’ve come from the tiny biotech firms getting swallowed whole.

And that’s because Big Pharma has a problem. Actually, several problems…

Patent cliffs are approaching. Competition is intensifying. Drug pipelines are aging. 

And developing entirely new therapy platforms internally is expensive, risky, and painfully slow.

So instead of building the next breakthrough from scratch, pharmaceutical giants are increasingly buying innovation outright.

And they’re paying enormous premiums to do it…

Over the past two years, we’ve seen an explosion of biotech acquisitions involving small companies with promising clinical-stage therapies, proprietary delivery systems, and next-generation treatment platforms. 

In many cases, these targets weren’t profitable. Some barely had revenue at all.

But they had something Big Pharma desperately wanted: potential.

That’s why investors willing to identify promising therapy platforms before the acquisition rumors start circulating could find themselves sitting on explosive upside.

And history suggests this trend is only accelerating…

Big Pharma Is Spending Billions to Refill Drug Pipelines

The merger-and-acquisition market across biotech has exploded as major pharmaceutical companies race to secure future growth. 

And analysts believe 2026 could become one of the biggest years for biotech dealmaking in recent memory as drugmakers confront looming patent expirations and slowing organic growth.

Just look at some of the recent deals…

Earlier this year, Johnson & Johnson agreed to acquire Intra-Cellular Therapies for roughly $14.6 billion. 

The attraction wasn’t just one drug. It was the company’s broader neuroscience platform and pipeline focused on mental health and neurological disorders.

Pfizer reportedly spent around $10 billion acquiring Metsera as competition in the obesity-treatment market intensified.

Meanwhile, Johnson & Johnson also agreed to buy Halda Therapeutics for more than $3 billion because of its RIPTAC cancer treatment platform, despite the company still being in the clinical development stage.

Bayer recently agreed to acquire Perfuse Therapeutics for up to $2.45 billion in a deal centered around an experimental therapy platform targeting glaucoma and diabetic retinopathy.

And Angelini Pharma just announced a $4.1 billion acquisition of Catalyst Pharmaceuticals to expand its rare disease and neurology footprint in the U.S. market.

Notice the pattern?

These aren’t mature companies getting bought because of stable cash flow. They’re emerging innovators with specialized therapy platforms and promising trial data.

That’s where the real value is migrating.

Why Small Biotech Platforms Have Become So Valuable

Modern drug development has changed dramatically…

Big Pharma no longer just wants a single blockbuster drug. It wants platforms that can produce multiple therapies across multiple diseases.

That’s why terms like CAR-T, antibody-drug conjugates, NK-cell therapies, gene editing, RNA therapies, and precision oncology have become so important.

One successful platform can generate an entire pipeline of future treatments.

And once clinical data begins showing promise, acquisition interest can arrive quickly.

This is especially true in oncology, autoimmune disease, neurology, and obesity treatments, where the market opportunities are measured in tens or even hundreds of billions of dollars annually.

The problem for retail investors is that by the time acquisition headlines hit the newswires, the easy money is usually already gone.

And that’s why the biggest gains often happen beforehand, when these companies are still flying under Wall Street’s radar.

Which is why keeping an eye on small clinical-stage biotech firms with differentiated technology platforms could become one of the most important speculative investment themes of the next few years.

Three Small Biotech Companies That Could Draw Acquisition Interest

One company that stands out in this environment is GT Biopharma (NASDAQ: GTBP).

GT Biopharma is developing an immuno-oncology platform focused on NK-cell engager therapies designed to target and destroy cancer cells. 

Unlike traditional T-cell therapies, NK-cell approaches could potentially offer safer treatment profiles, faster manufacturing, and broader applications across multiple cancer types.

The company’s TriKE platform has generated growing interest because it attempts to activate natural killer cells while simultaneously directing them toward cancer targets. 

That combination could eventually make therapies more effective while reducing some of the toxicity issues associated with older immunotherapy approaches.

Clinical-stage immunotherapy platforms have become one of the hottest acquisition categories in biotech because large pharmaceutical companies are aggressively competing to dominate the next generation of cancer treatment.

If GT Biopharma (NASDAQ: GTBP) can continue advancing clinical data and demonstrating platform versatility, it wouldn’t be surprising to see larger players begin paying muchncloser attention.

Another speculative name worth watching is Candel Therapeutics (NASDAQ: CADL)…

The company is developing viral immunotherapies designed to stimulate the immune system directly within tumors. 

Its platform combines viral vectors with immune activation strategies that could potentially enhance anti-tumor responses across several difficult-to-treat cancers.

What makes companies like this attractive acquisition candidates is scalability… 

If a platform demonstrates success in one indication, larger pharmaceutical companies immediately begin evaluating how broadly it can be expanded into additional cancer markets.

Then there’s Cargo Therapeutics (NASDAQ: CRGX), which is focused on next-generation CAR-T therapies designed to overcome resistance and relapse issues seen in existing blood cancer treatments.

CAR-T remains one of the most promising areas in oncology, but current therapies still face limitations tied to durability, manufacturing complexity, and patient relapse rates. 

Companies developing improved delivery mechanisms or enhanced targeting systems are attracting increasing attention across the industry.

That’s exactly the type of innovation larger pharmaceutical firms have been buying aggressively.

And remember, these acquisitions don’t always happen after Phase 3 trials or FDA approvals anymore…

Sometimes all it takes is compelling early-stage data and a platform that appears scalable.

The Window Before Wall Street Notices

Biotech investing is risky. There’s no way around that.

Clinical trials fail. Funding dries up. Regulators delay approvals. Promising therapies sometimes never make it to market.

But the rewards can also be enormous because success in biotech doesn’t always require full commercialization.

Sometimes success simply means attracting the attention of a bigger company with billions of dollars to spend and an urgent need to refill its pipeline.

That’s the environment we’re entering now.

Large pharmaceutical companies are sitting on mountains of cash while staring down patent expirations and slowing growth. 

At the same time, smaller biotech firms are developing revolutionary treatment platforms that could reshape entire areas of medicine.

That combination creates fertile ground for acquisition waves.

And investors who position themselves early could benefit long before the rest of Wall Street catches on.

That’s why now may be the time to start learning more about GT Biopharma (NASDAQ: GTBP), Candel Therapeutics (NASDAQ: CADL), and Cargo Therapeutics (NASDAQ: CRGX) before Big Pharma starts sniffing around and driving prices higher.

Because once acquisition rumors begin circulating, the market usually moves fast. And by then, a large chunk of the upside may already be gone.

Cancer is still the diagnosis nobody wants to hear.

It’s scary. It’s complicated. It’s personal. And it touches almost every family in some way.

But the story of cancer care has changed dramatically over the past several decades.

We’re no longer living in an age when doctors had just three blunt tools…

Cut it out, blast it with radiation, or poison it with chemotherapy and hope the cancer dies before the patient does.

Those tools still matter. Surgery, radiation, and chemotherapy remain major parts of cancer treatment. But they’re no longer the whole story.

Cancer Treatment Has Changed

Today, doctors can profile tumors by mutation. They can match patients with drugs designed for specific genetic drivers. They can use the immune system as a weapon. 

And they can deliver toxic payloads directly to cancer cells while sparing more healthy tissue. That’s a massive leap forward.

Thanks to those advances, the U.S. cancer death rate fell 34% from its 1991 peak through 2022, helping avert roughly 4.5 million deaths. 

That’s not a small improvement. It’s a revolution in slow motion.

We haven’t cured cancer. Not even close. But we’ve absolutely changed the odds.

The Market Is Following the Medicine

Now, here’s where the investment story begins…

Cancer isn’t just one disease. It’s hundreds of diseases hiding under the same ugly name.

Lung cancer isn’t breast cancer. Pancreatic cancer isn’t lymphoma. Melanoma isn’t ovarian cancer. 

And even within those categories, two patients with the “same” cancer can have very different molecular drivers.

That’s what makes oncology so hard. But it’s also what makes the market so enormous.

Every new insight creates a new target. Every new target creates a new drug candidate. Every new drug candidate creates a new clinical trial. 

And every successful clinical trial can create a new standard of care, a new revenue stream, and sometimes a multi-billion-dollar acquisition.

That’s why oncology remains one of the most valuable areas in all of health care.

Global spending on cancer medicines has already climbed into the hundreds of billions of dollars annually.

And analysts expect that number to keep rising as populations age, screening improves, treatment options expand, and more patients gain access to advanced therapies.

This isn’t growth for growth’s sake, though. There’s real demand behind it.

The American Cancer Society projects roughly 2.1 million new cancer cases and more than 626,000 cancer deaths in the United States in 2026. 

That’s about 5,800 new diagnoses every single day.

So yes, cancer care is a massive market. But it’s also a market driven by one of the most urgent needs in medicine. And that’s a powerful combination.

The Science Has Entered a New Phase

The old model of cancer treatment was largely based on location.

Where’s the tumor? Breast. Lung. Colon. Prostate. Blood. Brain.

While that still matters, increasingly, the more important question is: What’s driving the cancer?

Is there a mutation? A receptor? A protein? A pathway? A weakness the drug can exploit?

That shift has opened the door to targeted therapies, immunotherapies, antibody-drug conjugates, cell therapies, bispecific antibodies, radiopharmaceuticals, and other approaches that are reshaping cancer care.

Some of these treatments help the immune system recognize and attack cancer. Some act like guided missiles. Some block the signals cancer cells use to grow. 

Some bring immune cells and cancer cells into close contact so the body can do what it was designed to do.

It’s not clean. It’s not easy. And lot of experimental drugs fail. Some even fail after years of work and hundreds of millions of dollars are spent developing them.

That’s biotech.

But when it works, it can change lives. And when it changes lives, Wall Street notices.

Big Pharma Is Buying the Future

To see where Big Pharma thinks medicine is headed, don’t just listen to conference calls… You watch the checkbooks.

And if you’ve been watching then’ you’ve noticed that over the past few years, some of the biggest names in pharmaceuticals have spent enormous sums buying cancer platforms, cancer pipelines, and cancer drugs that started inside smaller, more focused companies.

Pfizer’s roughly $43 billion acquisition of Seagen is one of the clearest examples. 

That deal gave Pfizer a major position in antibody-drug conjugates, a class of cancer drugs designed to deliver cancer-killing agents more directly to tumor cells.

AbbVie made a similar move when it agreed to buy ImmunoGen for about $10.1 billion, strengthening its solid tumor pipeline and adding a targeted ovarian cancer therapy.

Bristol Myers Squibb also stepped deeper into oncology with its acquisition of Mirati Therapeutics, a deal valued at up to $5.8 billion including a contingent value right. 

That transaction added a targeted lung cancer drug and a broader cancer pipeline.

And those are just a few examples. But the bigger point is simple: Big Pharma needs innovation. And small biotech often creates it.

And when a little-known company develops something that could fill a pipeline gap, expand a cancer franchise, or threaten the current standard of care, the price tag can get very large very quickly.

The Patent Cliff Makes This More Urgent

There’s another force driving this trend: the patent cliff.

You see, big pharmaceutical companies live and die by exclusivity. A blockbuster drug can generate billions of dollars a year while it’s protected. 

But once generic or biosimilar competition arrives, sales can fall hard. And that creates a constant problem…

Big Pharma has to replace aging revenue streams before they roll over. And it’s often faster to buy innovation than to build it from scratch.

That’s why cancer-focused biotech companies can become so valuable even before they have major sales…

A promising platform, a strong mid-stage trial, or a treatment that works in a hard-to-treat cancer can turn a tiny company into a strategic asset.

The acquiring company isn’t just buying today’s revenue.

It’s buying tomorrow’s pipeline. It’s buying scientific talent. It’s buying intellectual property.

It’s buying a shot at the next standard of care. And in oncology, that shot can be worth billions.

This Is Where Speculation Lives

Now, let’s be honest. This isn’t like buying a railroad, a utility, or a dividend-paying toothpaste company.

Small biotech stocks are risky. Some are wildly risky. 

A single clinical trial result can make or break the whole story. A safety issue can wipe out years of progress. A financing problem can punish shareholders. A promising mechanism can look brilliant in early testing and disappoint in larger trials.

That’s why investors should never confuse excitement with certainty.

But speculation isn’t the same thing as gambling when there’s a real thesis behind it.

And in oncology, the thesis is pretty clear…

Cancer remains one of the world’s biggest medical problems. The market is enormous. The science is advancing. Big Pharma is hungry for pipeline assets. 

And the most explosive upside often starts in small companies most investors have never heard of.

That doesn’t mean every small cancer biotech is a winner. Many won’t be.

But the few that succeed can deliver life-changing advances for patients and portfolio-changing returns for early investors.

That’s what makes this corner of the market so fascinating…

It sits at the intersection of science, medicine, human need, and financial ambition.

Keep This Market in Focus

Cancer care has come a long way.

The death rate has fallen. Survival has improved. Treatments have become smarter. Patients have more options. Doctors have better tools. And researchers are still pushing.

That progress is the human story. And the investment story is what happens next.

Oncology is one of the few markets where scientific breakthroughs can create enormous social value and enormous financial value at the same time. 

That doesn’t make it safe. It doesn’t make it simple. And it sure doesn’t make every tiny biotech stock a future winner.

But it does make the cancer treatment market one of the most important places for investors to watch.

Because somewhere out there, a small company is working on a therapy that could change the way we treat cancer.

Maybe it fails. Maybe it gets bought. Maybe it becomes the foundation of the next great cancer franchise. That’s the opportunity.

So keep this market in focus. Keep watching the science. Keep watching the deal flow. 

And keep learning more about the small companies with big aspirations — and even bigger potential future profits.

Bankruptcy has a bad reputation and that makes sense. Nobody throws a party when a company collapses. 

Workers lose jobs. Investors get wiped out. Creditors start sharpening their knives. And lawyers show up by the truckload.

It’s not pretty.

But here’s the part most investors miss: Bankruptcy doesn’t always destroy value.

Sometimes, it reveals it…

That’s because a bankrupt company is often two very different things trapped inside the same ugly sweater.

On one side, you have the busted business. Too much debt. Bad management. Bloated costs. Poor timing. Maybe all of the above.

But on the other side, you often still have valuable assets…

Brands. Factories. Patents. Land. Customer relationships. Distribution networks. Intellectual property. Technology. Designs. Permits. Contracts.

The company may be dead, but the assets may be very much alive.

And throughout history, some of the smartest investors and operators have made fortunes by understanding that difference.

They didn’t buy the corpse… They bought the organs.

And then they built a new body around them.

The Twinkie That Came Back from the Dead

Hostess may be the most fitting (and delicious) example of this entire idea…

By 2012, the maker of Twinkies, Ding Dongs, Ho Hos, and other sugar-powered lunchbox legends was in bankruptcy. 

The company had iconic brands, but it was trapped under debt, legacy costs, labor fights, and an operating model that no longer worked.

To the casual observer, Hostess looked like a dead company.

But to Apollo Global Management and C. Dean Metropoulos, it looked like a fire sale on American nostalgia.

So, they stepped in…

They bought key Hostess snack-cake brands and bakeries. And that deal included Twinkies and other legendary Hostess products. 

But more importantly, it allowed the new owners to acquire the good assets without dragging along all the liabilities that helped sink the old company.

That’s the magic of many bankruptcy sales…

The buyer gets the good stuff. And the financial wreckage gets left behind.

Apollo and Metropoulos relaunched Hostess with a leaner cost structure, a modernized distribution model, and a renewed focus on the brands people still loved.

The Twinkie didn’t need to be invented. It just needed to be rescued.

And a decade later, J.M. Smucker agreed to acquire Hostess in a deal valued at roughly $5.6 billion.

That’s the bankruptcy treasure hunt in one snack-sized package…

A beloved brand fell into the ditch. Smart money pulled it out. Then Wall Street paid up.

Rust Belt Steel Became Wall Street Gold

Now let’s move from snack cakes to steel mills. Less delicious, but just as profitable…

In the early 2000s, American steel was about as popular as a root canal. 

Mills were going bankrupt. Pension obligations were massive. Foreign competition was brutal. Investors wanted software, not blast furnaces.

But Wilbur Ross saw something others didn’t. He saw that the steel assets themselves still had value.

The problem wasn’t necessarily the furnaces, mills, land, or industrial know-how. The problem was the old capital structure and legacy burden sitting on top of them.

So, Ross started buying bankrupt steel assets.

And he helped build International Steel Group by cobbling together mills from bankrupt companies, including pieces of LTV, Bethlehem Steel, and other distressed operators.

These were not glamorous assets. They were dirty, capital-intensive, and wildly out of favor.

Perfect… Because when nobody wants an asset, the price can get stupidly cheap.

Then the cycle turned and global steel demand improved. 

China was hungry for raw materials. Pricing recovered. The hated assets suddenly looked strategic again.

And in 2004, Mittal agreed to buy International Steel Group in a deal valued at about $4.5 billion.

That’s the second lesson…

Sometimes the best distressed deals aren’t about brands. They’re about capacity.

Factories. Mills. Infrastructure. Permits. Industrial assets that are difficult, expensive, and sometimes impossible to replace.

When the market hates them, they trade like scrap. But when the world needs them again, they trade like treasure.

Marvel Was an IP Vault In Disguise

Then there’s another household name that rivels Hostess: Marvel.

Today, Marvel is one of the most powerful entertainment brands on Earth. 

Iron Man, Captain America, Spider-Man, Black Panther, Thor, the Avengers — it’s hard to imagine modern pop culture without them.

But in the 1990s, Marvel was a mess…

The comic book bubble burst. Sales collapsed. The company filed for bankruptcy in 1996. 

And to many investors, Marvel looked like a fading comic book publisher tied to a shrinking market.

But that was the surface-level story. The deeper story was that Marvel owned a vault of characters with massive unrealized value.

The world didn’t need more comic books. It needed better ways to monetize stories.

Movies. Licensing. Toys. Video games. Television. Streaming. Merchandise. Theme parks. Global franchises.

Marvel eventually figured that out. And it stopped acting like a dying comic book company and started acting like an intellectual property machine.

By 2009, Disney bought Marvel for roughly $4 billion, completing one of the greatest entertainment turnarounds of the modern era.

And that’s the third lesson…

The most valuable asset in a distressed company may not look like an asset at all.

It may be a character, a patent, a design, a customer list, a license, a technical team, or a brand people forgot they still loved.

Marvel wasn’t saved because people suddenly became obsessed with bankruptcy proceedings.

It was saved because the underlying IP was worth far more than the market believed when the business was broken.

Pabst Proved Dead Brands Can Still Live

Pabst Blue Ribbon gives us another version of the same story…

PBR wasn’t a clean bankruptcy example like Hostess, but it fits the broader distressed-brand playbook beautifully.

It was old. It was tired. It certainly wasn’t winning the craft beer arms race. And it wasn’t exactly the future.

But then C. Dean Metropoulos bought Pabst in 2010 for about $250 million.

And a few years later, he sold it for around $700 million.

The genius wasn’t creating beer from scratch. The genius was recognizing that a forgotten brand still had cultural value.

PBR had history. Distribution. Recognition. A weirdly durable place in American drinking culture. It just needed the right owner and the right moment.

And that’s another key part of this strategy…

Distressed assets don’t always need a miracle. Sometimes they just need a better steward.

The Transfer of Value

All four stories point to the same big idea…

Bankruptcy and distress can create a transfer of value from weak hands to strong hands.

Hostess had beloved brands trapped inside a broken operating structure.

International Steel had hard industrial assets trapped inside a hated sector.

Marvel had priceless intellectual property trapped inside a collapsing comic book business.

Pabst had cultural brand equity trapped inside a tired beer company.

The buyers didn’t pay full price for perfection. They paid distressed prices for assets with a second life.

And that’s why this theme matters so much to investors today…

Because we’re entering an era where some of the most valuable assets in the world may not be snack cakes, steel mills, comic book heroes, or beer labels.

They may be nuclear reactor designs.

The Next Great Asset Transfer May Be Nuclear

Advanced nuclear energy is moving from science project to national priority in a hurry…

AI data centers need enormous amounts of reliable power. Industrial reshoring needs dependable baseload electricity. 

Remote mines, military bases, factories, islands, and off-grid communities need power that doesn’t depend on fragile fuel deliveries or overloaded transmission lines.

That’s why small modular reactors and micro modular reactors have moved from the fringe to the center of the energy conversation.

This isn’t the old nuclear story…

It’s not just about giant concrete domes that take decades, billions of dollars, and a small army of regulators to build.

This is about compact nuclear systems… Factory-built nuclear systems… Transportable nuclear systems…

Reactors that could one day power places the traditional grid can’t reach, won’t reach, or can’t serve reliably enough.

And right now, this emerging market may also be setting up one of the most fascinating distressed-asset stories in energy history.

Because one of the early pioneers in the space, Moltex Energy, has fallen into trouble…

Moltex Had the Kind of Technology the World May Soon Need

Moltex was not some random science project cooked up in a garage.

It was developing the Stable Salt Reactor-Wasteburner, or SSR-W, an advanced reactor concept designed to generate power using recycled nuclear waste.

That alone is a massive idea…

Nuclear power has always had two great public-relations problems: safety and waste. And Moltex was trying to attack both at once. 

Its reactor design was built around molten salt technology, and its broader pitch was simple but powerful: take used nuclear fuel, recycle it, and use it to generate clean, reliable baseload power.

In other words, take one of nuclear power’s biggest problems and turn it into fuel.

That’s not incremental. That’s potentially revolutionary.

Moltex had also developed WATSS, a technology intended to recycle used nuclear fuel. 

The company had reported progress in extracting transuranic material from used nuclear fuel, pushing forward the dream of turning yesterday’s nuclear waste into tomorrow’s clean power.

Again, that matters because the next energy boom won’t just be about building more power plants…

It’ll be about building better energy systems. Systems that are cleaner, more secure, more reliable, less dependent on foreign supply chains…

And capable of feeding the industrial, digital, and defense demands of the next decade.

Moltex seemed to have a real place in that story.

It had attracted government support. It had gained attention in Canada’s advanced nuclear push. 

It had been connected to plans in New Brunswick, where advanced reactor designs were being considered for future deployment.

This was not a dead idea. This was a valuable idea trapped inside a company that hit the wall.

A Broken Company Doesn’t Mean Broken Assets

This is where the distressed-asset angle becomes so important…

Moltex’s parent company entered administration, the British version of a bankruptcy-style insolvency process. 

The business and assets were put into a process where buyers could potentially step in.

And that creates the same kind of setup we saw in Hostess, International Steel, Marvel, and Pabst…

A company gets mismanaged. A company runs out of money. A company gets tangled in financial problems…

But the underlying assets may still have enormous value.

The designs still matter. The patents still matter. The technical work still matters.

The regulatory progress still matters. The team’s knowledge still matters.

The partnerships still matter. The market opportunity still matters.

And that’s the whole point…

The bankruptcy filing is not always the end of the story. Sometimes it is the beginning of the opportunity.

Especially when the asset sitting inside the wreckage is tied to a market as important as advanced nuclear energy.

The Smart Money Watches the Wreckage

The average investor sees bankruptcy and looks away but the smart investor always looks closer.

That doesn’t mean every distressed company is an opportunity. Most aren’t. 

Plenty of assets really are impaired. Plenty of businesses deserve to disappear. Plenty of turnarounds fail.

But every once in a while, distress creates a rare opening…

A valuable brand becomes available.

A steel mill changes hands at the bottom of the cycle.

A superhero library gets rescued from a broken comic book publisher.

A forgotten beer brand gets revived.

Or an advanced nuclear reactor design escapes a mismanaged company and lands in stronger hands.

That’s the story to watch now…

Moltex Energy’s distress process could become one of the most important value transfers in the nuclear market.

The company that wins the bid may gain access to advanced reactor designs, fuel-recycling technology, specialized expertise, and years of development work at a fraction of what it would cost to build from scratch.

And if that company can turn those assets into a real commercial platform, it could become the next multi-billion-dollar nuclear market unicorn.

So keep a close eye on the Moltex process… Watch for the winning bidder. Watch for the structure of the deal.

Watch for signs that valuable nuclear technology is moving from weak hands into stronger ones.

Because in business, value does not always disappear when a company falls apart…

Sometimes it simply changes owners.

And when that value involves advanced nuclear energy — one of the most important markets of the next decade — that transfer could be explosive.

The global energy map is being redrawn in real time.

The United Arab Emirates announced it will leave OPEC and OPEC+ effective May 1, delivering a major blow to the cartel’s ability to coordinate global oil production and pricing.

The UAE — one of the group’s largest producers — said it wants more flexibility to accelerate production and pursue its own long-term energy strategy.

This may be the clearest sign yet that President Donald Trump’s “global energy reset” is accelerating under the pressure of war, sanctions, and shifting trade routes.

For decades, OPEC and the Strait of Hormuz gave the Middle East enormous leverage over the global economy. Roughly a fifth of the world’s oil supply traditionally moved through that narrow waterway.

But the ongoing Iran conflict and repeated disruptions in Hormuz have exposed how fragile that system really is.

Trump’s response has been aggressive and transactional.

His administration has reportedly explored selective sanctions relief on Russian oil to stabilize global supply while simultaneously pressuring Iran and reshaping Venezuelan oil flows.

The strategy appears straightforward: weaken hostile chokepoints, increase non-OPEC production, and pull more global energy dependence toward American-aligned supply chains …

… All actions that seem to be pointed squarely at China.

China remains heavily dependent on imported oil from Iran, Russia, and the Middle East. Analysts have increasingly pointed to Beijing’s vulnerability around maritime chokepoints like Hormuz and the Strait of Malacca.

If global shipping lanes remain unstable, China faces higher transport costs, tighter energy supplies, and increased strategic vulnerability.

Meanwhile, the United States is in a far stronger position than it was during past oil shocks.

America remains one of the world’s largest oil producers thanks to shale production in places like Texas and North Dakota. If Middle Eastern instability persists and OPEC fractures further, U.S. producers could gain pricing power, export leverage, and geopolitical influence.

In the short term, oil volatility could intensify. Brent crude has already surged above $110 per barrel amid Hormuz disruptions.

But strategically, Washington appears to be positioning for something larger: a world where American energy, American shipping routes, and American-aligned producers matter more than centralized OPEC control.

If President Trump’s “global energy reset” keeps accelerating, investors should stop thinking only about oil prices and start thinking about who controls secure supply, export infrastructure, and politically stable production.

For example …

  • • Diamondback Energy (FANG)
    One of the purest plays on U.S. shale strength. If Middle Eastern instability keeps global supply tight, low-cost Permian producers like Diamondback could benefit from stronger realized pricing and rising export demand.
  • • Exxon Mobil (XOM)
    Exxon has massive upstream exposure, Gulf Coast refining capacity, and LNG infrastructure. It is also positioned to benefit if the U.S. increasingly becomes the “safe supplier” for allies trying to reduce exposure to unstable shipping lanes.
  • • Chevron (CVX)
    Chevron’s Venezuela exposure could become extremely important if Trump continues selectively reopening Venezuelan crude flows under U.S.-friendly arrangements. That would give U.S. majors leverage over barrels China once had easier access to.
  • • Occidental Petroleum (OXY)
    A Buffett-backed domestic oil name heavily tied to Permian production. If oil volatility stays elevated above historical averages, highly leveraged domestic producers could see major cash flow expansion.
  • • Kinder Morgan (KMI)
    Pipelines matter in an energy realignment. Moving oil and gas safely across North America becomes more valuable when global maritime chokepoints become less reliable.
  • • Cheniere Energy (LNG)
    One of the biggest potential winners if Europe and Asian allies continue diversifying away from unstable Middle Eastern supply and Russian energy dependence. U.S. LNG exports become strategically critical in that scenario.

Meanwhile, China could face the opposite setup.

Beijing still depends heavily on imported crude flowing through vulnerable maritime routes like the Strait of Hormuz and Strait of Malacca.

If those routes remain unstable, China absorbs higher shipping costs, insurance costs, and supply risk while the U.S. increasingly benefits from domestic production and export capacity.

This is starting to look less like a temporary oil spike and more like a long-term geopolitical restructuring of global energy power.

Most investors have heard the pitch for small modular reactors by now…

Build nuclear smaller. Build it faster. Deploy it closer to demand. Reduce cost overruns. Expand clean, reliable baseload power.

That’s a compelling story.

But there’s an even smaller, quieter, and potentially more disruptive story developing one layer below it…

I’m talking about micro modular reactors, or MMRs.

And if SMRs are meant to reshape the grid, MMRs could reshape the edge of the grid.

They’re designed for places where a full-size reactor is too big, diesel is too expensive, the power lines don’t reach, or reliability matters so much that you simply can’t afford to lose electricity for even a few minutes.

The U.S. Department of Energy describes them as compact, transportable systems that are generally designed to produce about 1 to 20 megawatts of thermal energy for electricity, heat, desalination, hydrogen, and other uses.

And that might not sound like much compared with traditional nuclear plants. But that’s the wrong way to think about it…

The right way to think about MMRs is this: they aren’t trying to replace every power plant in America.

They’re trying to serve the markets that big power plants and fragile grids don’t serve well.

And that’s where things start to get interesting.

The Nuclear Story Is Getting Smaller

For years, the nuclear conversation has revolved around scale…

Bigger plants. Bigger budgets. Bigger delays. Bigger political fights.

But advanced nuclear is flipping that old, tired logic on its head.

SMRs already challenged the assumption that nuclear has to mean one giant facility producing hundreds of megawatts.

But MMRs take that concept even further…

Description: An image of a Morpheus micro modular reactor. Source: Nuclea Energy Inc.

These are very small reactors, often designed to be factory-built, transported in modules, installed more quickly, and operated in places that would never make sense for conventional nuclear.

And the DOE says microreactors are attractive precisely because their small size can enable transportability and use in remote locations, military installations, and other hard-to-power settings.

That opens up a whole new category of demand…

Think isolated mining projects. Arctic communities. Oil and gas operations. Ports. Military bases. Disaster-response hubs. Remote industrial campuses.

Even certain data-intensive operations in places where fuel logistics and grid reliability are major problems.

In many of those markets, the alternative isn’t cheap natural gas or a massive solar farm with battery storage.

It’s often diesel. And diesel is ugly. It’s costly, dirty, logistically painful, and vulnerable to supply disruption.

That’s why MMRs matter…

They don’t need to beat every power source everywhere.

They just need to beat diesel, shipped fuel, or unreliable off-grid systems in enough niche markets to create a real commercial beachhead.

And once that beachhead is established, the market can grow from there.

Why MMRs Could Catch Investors Off Guard

This is the kind of trend the market often misses at first.

Investors love grand themes…

“The grid of the future.” “AI-powered electricity demand.” “The nuclear renaissance.”

Those narratives are easy to understand. They’re broad. They’re exciting. And they make for good headlines.

MMRs are a little different. They’re not as flashy because they sound so small.

But small can be a huge advantage…

A microreactor that fits into a transportable footprint and provides steady power and heat for years can be transformational in places where energy is a bottleneck.

BWXT’s Project Pele, for example, is a transportable microreactor sponsored by the U.S. Department of Defense and designed to generate at least 1.5 megawatts of always-on electricity while fitting into standard shipping-container logistics.

That tells you something important.

This isn’t just a science-fair concept. Serious institutions with serious energy-security needs are spending real money to move this technology forward.

The Pentagon is interested because energy resilience is national security.

The DOE is interested because microreactors could expand the commercial nuclear toolkit.

In fact, Idaho National Laboratory’s DOME test bed, which opened in April 2026, is specifically meant to accelerate real-world microreactor experiments.

Once you have government-backed testing, regulatory engagement, and early industrial use cases lining up, you no longer have just a concept. You have an emerging market.

And emerging markets are where the biggest gains usually start.

Where The Real Opportunity Could Be

The beauty of MMRs is that they don’t need universal adoption to become a major trend.

They just need to dominate specific, underserved energy niches.

Remote mining is a perfect example…

Mining projects often sit on top of strategic resources but far away from reliable power infrastructure.

If a company can bring in transportable nuclear power that runs for years and reduces dependence on diesel, the economics of certain projects could improve dramatically.

That matters in a world increasingly obsessed with domestic supply chains for copper, nickel, uranium, rare earths, and other strategic materials.

Military applications are another obvious market…

The U.S. government has made it clear that resilient, always-on power for installations and remote operations is a priority.

That’s why Project Pele exists, and it’s one reason microreactors may move faster than many investors expect.

Then there’s industrial heat…

A lot of investors still think about nuclear only as electricity. But microreactors can also provide high-temperature heat for industrial processes, which opens another door entirely.

DOE notes that microreactor output can be used directly as heat or converted into electricity, broadening the addressable market beyond just power sales.

That flexibility matters…

It means MMRs could eventually become a solution not just for electricity shortages, but for energy resilience, fuel substitution, industrial efficiency, and strategic infrastructure buildouts.

And that’s a much bigger story than most people realize.

The Companies Quietly Pushing This Forward

This is still a small and relatively unknown corner of the energy market, which means pure-play options are limited and risk is high.

But that’s also what makes it interesting.

Westinghouse is developing the eVinci microreactor for decentralized and remote applications.

And its owners include Cameco and Brookfield through their Westinghouse stake.

Westinghouse also became the first microreactor developer to secure an approved Preliminary Safety Design Report for DOME in 2025, a meaningful milestone for future testing and commercialization.

BWXT is a name we’ve already mentioned that’s worth watching…

It’s already deeply embedded in nuclear manufacturing and defense work, and it has exposure to both Project Pele and its own BANR microreactor platform.

The company says BANR is a factory-fabricated, transportable high-temperature gas reactor for remote power and industrial heat production.

And NANO Nuclear is one of the more direct public-market names in this space.

The company trades on Nasdaq under the ticker NNE and says it is focused on portable and stationary microreactor technologies.

It also acquired major assets tied to the bankrupt Ultra Safe Nuclear effort and later finalized the acquisition of Global First Power, which had been linked to the Chalk River MMR project in Canada.

That last part is worth pausing on…

Not every project in this space will succeed cleanly.

The Chalk River MMR project was paused after the original USNC effort ran into bankruptcy, and Canada’s nuclear regulator still lists the Global First Power project as paused.

That’s the risk side of the story.

This is early-stage technology. Licensing takes time. Fuel supply matters. Execution will separate the winners from the wannabes.

But early-stage messiness is not a reason to ignore a market. In many cases, it’s the price of admission.

Why This Could Become a Major Energy Trend

The energy world is changing in a way that favors technologies like MMRs.

Power demand is getting more fragmented. More strategic. More local. More resilience-focused.

It’s no longer just about feeding giant cities from giant power plants.

It’s about securing remote assets, supporting industrial clusters, hardening military infrastructure, and keeping critical operations online no matter what the grid is doing.

That’s exactly the kind of environment where micro modular reactors can thrive.

SMRs may still get the headlines… They’re easier to plug into the broader grid narrative.

But MMRs may wind up being the stealthier opportunity because they target the edge cases where the value of dependable energy is highest and the competition is weakest.

That’s often where the market’s next big winners are born.

The crowd tends to arrive after a theme becomes obvious. But smart investors start paying attention when the market still feels obscure, complicated, and just a little too early.

That’s where micro modular reactors are today…

Not mainstream. Not fully commercial. Not risk-free.

But very real. Advancing. Backed by serious institutions. And aimed directly at a set of energy problems that are only becoming more important.

So, if you want to get ahead of one of the next major trends in advanced nuclear, this is where you should be looking now.

Learn more about the companies building the hardware, supplying the fuel, solving the logistics, and pushing these reactors toward real deployment.

Because by the time this market feels crowded and obvious, the easy money may already be gone.